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ABSTRACT 
 
The post-translational modification of troponin by phosphorylation is a central 
mechanism to modulate calcium activated cardiac contraction. Over 95% of 
phosphorylation in the heart occurs on serine or threonine residues. It has been recently 
shown that phosphorylation of the troponin inhibitory subunit (TnI) at Tyr-26 is 
decreased in human heart failure with functional effects such as decreasing thin filament 
calcium sensitivity and accelerating calcium dissociation. This discovery has lead us to 
hypothesize that the phosphorylation of the other tyrosine residues in TnI, including TnI 
Tyr-29, Tyr-112 (and TnI Tyr-134 found mouse cardiac muscle), will also exhibit 
functional effects. Kinase prediction calculation suggests that these additional tyrosine 
residues are even more likely to be phosphorylated than Tyr-26. To test the regulatory 
effects of TnI Tyr-phosphorylation, we generated, expressed and purified cardiac TnI 
containing phosphomimetic substitutions (Tyr to Glu or Tyr to Asp). Purified proteins 
were used to form the troponin complex and functional effects determined by measuring 
calcium binding to Troponin C (TnC) in reconstituted thin filaments. Our results confirm 
Tyr-26 pseudo-phosphorylation decrease calcium binding to TnC on the thin filament and 
demonstrate a similar decrease in calcium binding to TnC with the pseudo-
phosphorylation of Tyr-29 in thin filaments containing human cardiac TnI and thin 
filaments containing mouse cardiac Tyr- 134 TnI. To investigate the effects of TnI Tyr 
phosphorylation on myofilament deactivation, we measured the rate of calcium 
dissociation from TnC. Results demonstrate filaments containing Tyr-26 and Tyr- 29 
pseudo-phosphorylated TnI accelerate the rate of calcium dissociation from TnC. Based 
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upon these results we conclude that the pseudo-phosphorylation of TnI at these additional 
Tyr-residues play a functional role in modulating force production of the heart.  
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Chapter 1- Background 
 
General Heart Function  
The heart is the central pump of the circulatory system. During the cardiac cycle, 
the heart cyclically contracts and relaxes, providing a continuous circulation of blood, 
nutrients and oxygen throughout the body, as well as the continuous removal of wastes 
from the body organs. Performance of the heart is measured as the cardiac output (CO), 
which is dependent on the heart rate and stroke volume. Stroke volume is the amount of 
blood ejected by the left ventricle in one contraction. Physiological and pathological 
changes in body blood demand cause compensatory alterations of the cardiac muscle 
contraction and the blood pumped to maintain necessary blood (nutrients, oxygen and 
waste removal). In addition to contraction performance of the heart to change the volume 
of blood pumped, cardiac output is also dependent on the heart rate. After contraction 
there is a period of cardiac diastole, where the heart refills with blood due to relaxation of 
the cardiac muscle. Relaxation must also be altered to maintain an adequate volume of 
blood pumped by the heart. Increased heart rate requires quicker contraction and 
relaxation. Upon increased heart rate the hearts’ ability to fill (eg. lusitrophy-the 
relaxation of the heart muscle) is important to maintain CO. If the muscle is unable to 
adequately relax, the heart will not fully fill before the next contraction cycle resulting in 
less blood volume being pumped at the next contraction. Therefore the modulation of 
both cardiac contraction and relaxation are critical to match the heart’s supply of blood to 
the body. 
	   6	  
There are many causes of heart disease but heart disease is ultimately the inability 
of the heart to pump adequate blood to meet the bodies demand for oxygen and/or 
nutrients. Cardiovascular disease (CVD) is the leading global and US cause of death, 
accounting for more than 17.3 million deaths per year [1]. There is currently no treatment 
for heart disease except heart transplant, and current therapeutics are ineffective.  
Reversing the negative changes that occur in heart failure and/or improving heart 
contractile function allowing heart to meet the body’s demand could be beneficial. One 
mechanism to improve heart contractile function would be to design new therapies, 
however we must first understand the basic mechanism’s responsible for the 
physiological and pathological changes in heart contraction. Conducting research to 
continue to learn and understand the functions of the heart will allow us to gain a closer 
insight on heart disease and potential possibilities to reverse or exploit these changes to 
modify the effects.  
 
Regulation of Cardiac Contraction: Excitation-Contracting Coupling 
The heart is a muscle composed of myocytes consisting of myofibril bundles 
containing myofilaments. These myofibrils have distinct, repeating units known as 
sarcomeres, which are the basic contractile units of the myocyte. The sarcomere is 
composed of thick and thin filaments –myosin and actin. The length of the sarcomere can 
be altered by physiological “sliding” interactions between actin and myosin [2]. The 
sliding of actin over myosin causes the sarcomere length to shorten, contraction of the 
cell and the subsequent production of force. The process of myocyte contraction occurs 
through a series of events called excitation-contraction coupling. Excitation-contraction 
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coupling is the process where an action potential triggers a cardiac myocyte to contract 
[2]. The thin filament associated regulatory proteins are responsible for regulating actin 
and myosin interactions, and thus force production. There are three states of the thin 
filament that regulate the actin-myosin cross bridge; blocked, closed and open [3-5]. In 
the blocked state the myosin-binding site on actin is sterically blocked by tropomyosin, in 
the closed state the myosin-head is bound weakly to the actin and in the open state the 
myosin head is strongly bound to actin and able to undergo the force producing power-
stroke motion sliding actin to shorten the sarcomere. This state of the thin filament is 
regulated by calcium (the signal molecule), which controls the contraction and relaxation 
of the chambers of the heart. In the absence of Ca2+, the TF resides in the “blocked” state. 
Upon stimulus to contract, an action potential depolarizes a myocyte that causes a small 
amount of calcium ions to rush into the myocyte through L-type calcium channels. These 
calcium ions trigger the release of sarcoplasmic reticulum-stored calcium through the 
calcium-release channel known as the Ryanodine receptor during a process called 
calcium-induced-calcium-release. Intracellular calcium concentration significantly 
increases, and free calcium subsequently binds to the troponin complex at the 
myofilament. The binding of Ca2+ to troponin causes a conformational change, initiating 
the movement of tropomyosin from its blocking position on actin to the “closed” state of 
the thin filament. A myosin-binding site on the actin is exposed so that the myosin head 
weakly binds and the strong binding of myosin induces the “open” state. In the open 
state, the myosin ATPase results in ATP hydrolyses that supplies energy for a 
conformational change in the actin-myosin complex powerstroke. The powerstroke of 
myosin displaces actin, occurring in a sliding motion, shortening the sarcomere. 
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Contraction occurs when the filaments slide over one another in a series of repetitive 
myosin powerstroke events. As long as there is sufficient intracellular calcium such that 
the calcium remains bound to TnC, the thin filament remains in the “open” state and 
myosin cycling continues. 
 Relaxation occurs after the end of this contraction phase when an ATP-dependent 
calcium pump, sarcoplasmic/endoplasmic reticulum calcium ATPase, moves calcium 
back to the sarcoplasmic reticulum and a sodium-calcium-exchange pump transports the 
remaining extra calcium out of the muscle cell simultaneously. The intracellular calcium 
concentration is now lowered and calcium is released from troponin, inducing a 
conformational change in the troponin complex, and tropomyosin resumes a position on 
actin to block the myosin-actin binding site.  
 
Detailed mechanism of Troponin regulation 
The thin filament consists primarily of the protein actin, which contains a myosin-
binding site, where the myosin molecule has the ability to bind its head. Tropomyosin 
molecules contribute to blocking these active sites during muscle relaxation in addition to 
the troponin protein molecules. Troponin is a vital protein switch that affects heart 
contraction and relaxation through binding the calcium signal. Troponin (Tn) is a 
complex of three regulatory proteins (troponin C, the calcium binding subunit; troponin I, 
the inhibitory subunit; and troponin T, the tropomyosin binding subunit). Troponin T 
binds to tropomyosin, interlocking them to form a complex. In the absence of calcium, 
the TnI C-terminal inhibitory peptide binds actin, contributing to an actin-myosin 
inhibition. Upon increased intracellular calcium beyond TnC affinity, calcium ions bind 
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to TnC to produce conformational changes in TnC that are relayed to the entire troponin 
complex. Calcium mediated changes in the TnC N-terminus expose a hydrophobic 
“sticky patch” that binds the TnI C-terminal switch peptide removing TnI-actin inhibitory 
binding [1]. With the removal of TnI and changes in TnT, tropomyosin movement is 
allowed and actin-myosin interaction contraction is ensured. Contraction inhibition is 
achieved by reverse of this process. 
Troponin I Modulation in the regulation of contraction/force 
 With each beat of the heart, every cardiomyocyte contracts. These myocytes are 
not fully activated with every contraction. In the heart muscle you can therefore increase 
contraction by activating more Tn resulting in increased myosin binding to actin. This is 
in opposition to skeletal muscle where the individual skeletal muscle cells and troponin 
molecules are always fully activated each time the cell contracts. The degree of cardiac 
contraction is determined by the force (number of myosin molecules interacting with 
actin) and rate (cycling of these myosin cross-bridges) of the heart muscle. While many 
mechanisms exist to modulate cardiac contraction, changes in calcium binding to Tn are a 
primary mechanism of contractile modulation. The post-translational modification of Tn 
by phosphorylation is a significant physiological/pathological mechanism to modulate the 
interaction of actin and myosin and therefore contraction. These phosphorylations can 
result in changes in both force and rate by altering calcium binding to TnC and the 
amount of thin filament activation. Phosphorylation of Tn characterizes a primary 
mechanism to alter the responsiveness of troponin to calcium and modulate calcium-
dependent thin filament regulation of myosin’s interaction with actin and consequently 
the force of cardiac muscle.  
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The best-known mechanism of cardiac contractile modulation occurs through 
beta-adrenergic receptor (BAR) stimulation and phosphorylation of Tn; specifically at 
TnI serines  23 and 24 [6-7]. Unless otherwise noted, the reference to all TnI amino acid 
numbers is derived from the human TnI sequence. TnI, the inhibitory subunit of the 
troponin complex can be phosphorylated at multiple sites [8], which is a key regulatory 
mechanism to alter the calcium regulation of contraction via sensitivity (the affinity of 
calcium to binding to TnC of the troponin complex and the resulting force production of 
the myocyte upon binding). Upon BAR stimulation, the activation of protein kinase A 
(PKA) results in the phosphorylation of TnI at Ser-23 and Ser-24 that through changing 
Tn structure and function, results in altered TF regulation to modulate contractile 
function [9]. This results in decreased calcium sensitivity (which is a decrease in calcium 
affinity of binding to TnC) resulting in decreased contraction [10]. As calcium sensitivity 
decreases, it takes more calcium to attain the same contractile force production and 
provide the necessary volume of blood to the body because of the lower affinity for 
calcium to bind to the TnC-calcium complex resulting in less Tn molecules activated. 
Decreased calcium sensitivity leads to less Tn being activated, and therefore, less myosin 
molecules that can bind actin ultimately causing less force production. In addition, TnI 
phosphorylation results in accelerated calcium dissociation from the TnC-calcium 
complex (a lower affinity for calcium to stay bound). As calcium dissociation is 
increased, relaxation of the heart muscle is achieved more quickly, allowing the muscle 
to fully expand and fill with blood to the necessary volume for normal heart pumping. 
This affects the hearts’ performance in responding to environmental and internal changes 
to the body.  
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TnI Phosphorylation at Novel Tyr-26 residue 
 It has recently been shown that a novel phosphorylation of TnI occurs in the 
human heart at tyrosine 26 (TnI Tyr-26) [12]. This is the only myofilament tyrosine 
phosphorylation to be identified to occur. Zhang and colleagues further showed this novel 
TnI Tyr-26 phosphorylation is reduced by ~ 43% in the failing human heart and models 
suggesting a role during cardiac pathology [12]. We have further determined the effects 
of TnI Tyr-26 phosphorylation on cardiac muscle. We demonstrated phosphate 
incorporation and pseudo-phosphorylation at TnI Tyr-26 decreases Ca2+-sensitive 
development of force and thin filament activation as well as that TnI Tyr-26 pseudo-
phosphorylation accelerated thin filament Ca2+ dissociation [13]. We propose that by 
decreasing Ca2+-sensitivity, the heart’s ability to function properly will be diminished 
because the heart will need more calcium than normally present to contract at a force 
capable of supplying proper blood to the body. Alternately, relaxing at a hastened rate, 
the heart will expand faster, filling with more blood and pumping more blood during the 
next contraction phase.  
Tyrosine phosphorylation has not been extensively studied as a direct mechanism 
to modulate cardiac contraction. In addition, there are no demonstrations of myofilament 
tyrosine phosphorylation to alter heart function or tyrosine signaling by separate kinases 
from Ser/ Thr. TnI tyrosine phosphorylation therefore represents a novel phosphorylation 
pathway to differentially modulate cardiac contractile function through Ca2+ sensitivity 
and thin filament deactivation. 
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Kinase prediction software predicts that kinases are as likely, if not more likely, to 
phosphorylate the additional human tyrosine residues, Tyr-29, Tyr-112 and mouse Tyr-
134, of TnI than the Tyr-26 site. The discovery of the functional effects of TnI Tyr-26 
phosphorylation has lead us to hypothesize that the phosphorylation of additional sites in 
the TnI inhibitory subunit, including Tyr-29, Tyr-112 and Tyr-134 will also exhibit 
functional effects on cardiac contraction. In human, Tyr-133 is a non-phosphorylatable 
phenylalanine (Phe, F) while the corresponding mouse TnI residue is a tyrosine (Tyr-
134). Due to a different number of amino acids in humans, F133 is the same TnI residue 
as mouse Y134. Our 2nd hypothesis proposes that the presence of the non-
phosphorylatable phenylalanine residue in human TnI, in place of the phosphorylatable 
Tyr in mouse TnI, results in a loss of the Tyr-134 regulatory site found in mouse cardiac 
muscle.  
Phosphorylation sites and classical Ser/Thr signaling pathways of cardiac TnI, 
such as TnI Ser 23/24, have important physiological and patho-physiological cardiac 
functions. Unlike these residues, cardiac TnI tyrosine phosphorylation has not been 
extensively studied. In addition, soluble tyrosine kinase signaling is not as prevalent and 
has not to date been demonstrated as a regulatory signaling pathway to directly alter 
cardiac contraction. We therefore propose that TnI tyrosine residue phosphorylation 
represents a novel phosphorylation pathway to differentially modulate cardiac contractile 
function through Ca2+ sensitivity and thin filament deactivation. 
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Chapter 2- Methods 
 
cDNA constructs 
All cardiac TnI residue numbers presented in this manuscript are given according 
to the native human sequence including the first methionine.  
Site-directed mutagenesis (QuickChange Lightning, Agilent, Santa Clara, CA) 
was conducted according to manufacturer’s instructions as previously described [10] to 
generate cDNA constructs encoding human and mouse TnI pseudo-phosphorylations: 
Tyr-26 to Glu (Y26E), Tyr-26 to Asp (Y26D), Tyr-29 to Glu (Y29E), Tyr-134 to Glu 
(Y134E).  All resultant constructs were verified by DNA sequencing. 
 
Protein expression and purification  
Plasmids encoding the individual recombinant human cardiac Tn subunits were 
transformed, expressed in Escherichia coli and purified to homogeneity as previously 
described [3, 6, 7]. TnCC35S,T53C,C84S was labeled with 2-(4’-
iodoacetamidoanilo)naphthalene-6-sulfonic acid (IAANS) as previously described [8, 9]. 
Cardiac Tn complexes were prepared by reconstitution of the individual subunits and 
sequential dialysis as previously described [6]. Rabbit skeletal actin and bovine cardiac 
tropomyosin were prepared from acetone powder as previously described [10-13]. Thin 
filaments were reconstituted as previously described [7].  
 
Thin filament steady-state Ca2+ binding to TnC 
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Steady-state fluorescence measurements were conducted using a Perkin-Elmer 
LS55 spectrofluorimeter. IAANS fluorescence changes of labeled TnC in reconstituted 
thin filaments upon addition of various Ca2+ were monitored as previously described [10, 
13]. Briefly, fluorescence was monitored from reconstituted thin filaments containing 
various TnI mutations in buffer (in mM; 150 KCl, 3 MgCl2, 2 EGTA, 200 MOPS, pH 
7.0) at 15°C with constant stirring. Calcium sensitivities of conformational changes are 
reported as the dissociation constant (Kd), representing a mean of titrations. 
 
Ca2+ dissociation from TnC in the thin filament  
Ca2+ dissociation from TnC in thin filaments containing wild type (WT) or mutant 
TnI was measured in calcium saturated buffer (in mM; 150 KCl, 3 MgCl2, 0.2 Ca2+, 10 
MOPS, pH 7.0) upon rapid mixing with EGTA buffer at 15°C in a stopped flow 
instrument (Applied Photophysics Ltd. model SX.18 MV) with a dead time of 1.4 ms as 
previously described [10, 14] and kinetic values obtained. Katherine Baruk generated and 
made the thin filaments for these measurements and all calcium dissociation 
measurements presented in this thesis were collected by Shane Walton in Dr. Jonathan 
Davis’s laboratory at The Ohio State University. 
 
Data processing and statistical analysis  
Data are presented as mean ± the standard error of the mean. Normalized steady-
state Ca2+ binding values were fit with a logistic sigmoid function mathematically 
equivalent to the Hill equation to determine 50% maximal binding as previously 
described [6, 11]. Kinetic values of Ca2+ dissociation were fit using a program (by P. J. 
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King, Applied Photophysics Ltd.) utilizing the nonlinear Levenberg-Marquardt algorithm 
[14]. Results of steady-state Ca2+ binding and Ca2+ dissociation were compared by 1-way 
ANOVA with Tukey’s post-hoc test. P<0.05 was considered statistically significant. 
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Chapter 3- Effects of Human TnI Tyr Phosphorylation 
 
Introduction 
The heart pumps blood containing nutrients and oxygen systemically throughout 
the body as a result of the contraction and force development of the cardiac muscle cells. 
The magnitude of cardiac contraction and its rate of relaxation are influenced by 
intracellular Ca2+ binding to the troponin complex to activate the thin filament allowing 
myosin’s interaction with actin. Calcium binding to troponin (Tn) is a significant 
component of thin filament regulation of the actin myosin interaction and therefore, heart 
contraction. Phosphorylation of the cardiac troponin inhibitory subunit (TnI) modulates 
thin filament activation and cardiac contraction. Troponin I residue Tyr-26 has previously 
been identified as a novel TnI phosphorylation residue in the heart [12]. Recent work has 
identified that TnI Tyr-26 phosphorylation is present in the normal human heart and its 
phosphorylation is decreased during heart failure [12]. Our lab demonstrated that both the 
incorporation of phosphate and pseudo-phosphorylation at the TnI Tyr-26 residue 
decreases and the Ca2+-sensitive development of force as well as accelerates thin filament 
Ca2+ dissociation [13]. The human cardiac TnI subunit has two additional tyrosine 
residues, including Tyr-29 and Tyr-112. Kinase prediction software suggests that these 
additional TnI Tyr residues are even more likely to be phosphorylated in the human heart 
than Tyr-26. We hypothesized that the phosphorylation of these sites will also alter 
calcium sensitivity and calcium dissociation from the troponin complex in the thin 
filament. To test the regulatory effects of these other TnI tyrosine phosphorylations, we 
generated, expressed and purified human cardiac TnI containing phosphomimetic 
	   17	  
substitutions (Tyr to Glu or Tyr to Asp). Purified proteins were used to form the troponin 
complex and functional effects determined by measuring steady-state calcium binding to 
and dissociation from troponin C (TnC) in reconstituted thin filaments. We found that 
pseudo-phosphorylation of human cardiac TnI at residues Tyr-26 and Tyr-29 decreases 
calcium sensitivity and accelerates calcium dissociation. These identified contractile 
effects of the TnI Tyr phosphorylations suggest that the phosphorylation of these sites 
may be significant to modulate contractile function and present a novel pathway to 
modulate heart function.  
 
Methods 
See chapter 2.  
 
Results 
Our lab previously demonstrated that the phosphorylation of TnI at residue Tyr-
26 decreased thin filament calcium sensitivity and accelerated calcium dissociation [13]. 
We further hypothesized that the phosphorylation of the additional Tyr-29 residue of TnI 
will also exhibit similar functional effects. To investigate the functional properties 
elicited by TnI Tyr-29 we first needed to construct, express and purify human wild-type 
troponin (hTnWT) and pseudo-phosphorylated TnI, mimicking phosphate incorporation. 
The cDNA clones encoding pseudo-phosphorylated TnI consisting of human cardiac TnI 
with Tyr-26 mutated to Glu (hTnY26E), human cardiac TnI With Tyr-26 mutated to Asp 
(hTnY26D), and human cardiac TnI with Tyr 29 mutated to Glu (hTnY29E) were 
generated by PCR. Resulting TnI clones and the other troponin subunits were expressed 
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in E. Coli. The resulting troponin subunits and associated thin filament proteins were then 
purified to homogeneity as demonstrated in figure 1. Next we determine the effect of 
hTnWT on Ca2+ regulation. Thin filaments were reconstituted with actin, tropomyosin 
and hTnWT and thin filament activation measured as the change in IAANS fluorescence 
upon steady-state Ca2+ binding to TnC. Consistent with our labs’ previous studies, the thin 
filaments containing hTnWT exhibited a pCA50 of 5.8 +/- 0.037, n=14 (Fig 2) [13].  
We next sought to verify the functional effects of hTnY26 pseudo-
phosphorylation. We previously demonstrated the incorporation of phosphorylate at 
hTnY26E decreases the calcium-sensitive force production of cardiac muscle [13]. 
Performing steady-state calcium-binding experiments in reconstituted thin filament we 
confirmed that the hTnY26E and hTnY26D both decrease calcium binding to TnC 
similarly to which was seen previously by our lab. Results demonstrate thin filaments 
containing hTnY26D exhibited a pCa50 of 5.476 +/- 0.0551, n=3 and hTnY26E also 
exhibited a pCa50 of 5.476 +/- 0.0263, n=6. Comparing these values to the pCa50 of 
hTnWT (pCa50 = 5.802 +/- 0.037; Fig 2), we see that the pseudo-phosphorylation of Tyr-
26 statistically decreases calcium sensitivity in the thin filament by +0.326 +/- 0.0107 and 
+0.326+/- 0.0181 pCa50 units, respectively for hTnY26E and hTnY26D (Fig 2) [13]. 
Thus, our results demonstrate we were able to confirm previous measurements for 
hTnWT, hTnY26E and hTnWT. 
To investigate the effect of the additional phosphorylatable tyrosine residue site 
hTnY29 on Ca2+ regulation, the change in IAANS fluorescence upon steady-state Ca2+ 
binding to TnC in the reconstituted thin filament was measured for human cardiac TnI 
containing pseudo-phosphorylated Tyr-29 mutated to Glu (hTnY29E). Thin filaments 
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containing the hTnY29E exhibited a pCa50 value of 5.4775 +/-0.02312, n=3 (Fig 2). This 
value is nearly identical to the pCa50 exhibited by hTnY26D and hTnY26E demonstrating 
that the phosphorylation of these sites decrease calcium sensitivity of the thin filament to 
a similar degree. 
Additionally, we looked at the dissociation rate of calcium from TnC of each 
pseudo-phosphorylated TnI in the isolated troponin [13,15]. We observed that the Ca2+ 
dissociation, measured as the average change by IAANS fluorescence by stopped-flow, 
from TnC in isolated troponin containing WT or pseudo-phosphorylated human cardiac 
TnI exhibited no significant decrease in the rate of calcium-dissociation from isolated 
troponin (rate of calcium dissociation: hTnWT = 42.27 +/-0.75 /s, hTnY26D = 45.11 +/-
2.99 /s, hTnY26E = 42.85/s +/-1.38, hTnY29E = 43.87+/-2.87 /s; p>0.05; Fig 3). 
However, when thin filaments were reconstituted with Tn containing pseudo-
phosphorylated TnI Y26 or Y29 we observed the rate of Ca2+ dissociation from TnC in 
the thin filament was significantly accelerated when compared to those thin filaments 
containing hTnWT (rate of hTnWT= 108.77 +/-1.19 /s, hTnY26D = 403.6 +/-22.23 /s, 
hTnY26E = 353.49 +/-14.43 /s, hTnY29E = 297.18 +/-21.02 /s; p<0.05; Fig 4). This data 
demonstrates that the pseudo-phosphorylation of TnI Tyr residues in the thin filament 
dramatically accelerates calcium dissociation from the thin filament and suggests when 
these TnI tyrosine residues are phosphorylated in the cardiac muscle they will accelerate 
cardiac muscle relaxation.  
 
Discussion 
	   20	  
This study aimed to confirm the contractile regulatory properties elicited by the 
novel N-terminal phosphorylation of TnI at Tyr-26 recently identified in the heart [11,12] 
and further assess the functional properties elicited by phosphorylation of the additional 
human TnI Tyr-29 residue. Findings of this study validate previous data from our lab 
[12].  In addition, major findings demonstrate that hTnY29E exhibited decreased calcium 
sensitivity similarly to hTnY26E in addition to similarly accelerated calcium dissociate 
rate. These findings support the significance of TnI Tyr-29 phosphorylation to increase 
thin filament deactivation, and in turn, may have an importance for increased cardiac 
relaxation. We propose that TnI Tyr-29 phosphorylation is beneficial during exercise for 
it has the ability to increase the heart rate due to its increase in heart relaxation, allowing 
the heart to get ready to contract more quickly. TnI Tyr-26 phosphorylation is associated 
with contractile modulation during heart failure [12]. Tyr-26 phosphorylation was shown 
to be decreased in the failing heart and that this increase may potentially contribute to the 
increased calcium sensitivity during heart failure [27]. Additionally, we propose that the 
decrease in the phosphorylation of TnI Tyr-29 may be good in heart failure because a 
decrease of its presence will obtain an increase in force production from contraction of 
the heart. The presence of inherently phosphorylated TnI Tyr-26 suggests it plays a role 
in maintaining normal heart function [12]. Our findings suggest the presence of TnI Tyr-
29 phosphorylation may also play a role in normal and/or pathological heart function.   
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Contraction and force development of the cardiac muscle cells’ determine the 
volume of blood containing nutrients and oxygen that the heart pumps systemically 
throughout the body. Intracellular calcium levels influence these processes. Calcium 
binding to troponin (Tn) is a significant component of thin filament regulation of the 
actin myosin interaction and therefore, heart contraction. Human tyrosine residue 26 in 
the inhibitory subunit of the cardiac troponin complex troponin I (TnI) has previously 
been identified as novel phosphorylated residue in TnI and recent work has determined 
that TnI Tyr-26 phosphorylation is present in the normal human heart and is decreased 
during heart failure [12]. Our lab has demonstrated that the incorporation of phosphate or 
pseudo-phosphorylation at TnI Tyr-26 decreases the Ca2+-sensitive development of force 
and thin filament activation as well as accelerates thin filament Ca2+ dissociation [12]. 
The mouse cardiac TnI subunit has an additional potential tyrosine phosphorylation site 
at Tyr-134 that through differential evolutionarily selection resulted in the human TnI 
sequence consisting of a non-phosphorylatable phenylalanine residue (Phe-133). Human 
cardiac TnI Phe-133 is the same residue as mouse cardiac Tyr-134 due to mouse TnI 
containing the addition of an alanine residue at position 25 that is not present in the 
human TnI. We hypothesized that calcium binding in thin filaments containing pseudo-
phosphorylated mouse cardiac TnI with Tyr-134 mutated to Glu (mTnY134E) will have a 
functional effect similar to that of mTnY27E. To test the regulatory effects of these other 
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mouse TnI Tyr-phosphorylations, we generated, expressed and purified cardiac TnI 
containing phosphomimetic substitutions (Tyr to Glu). Purified proteins were used to 
form the troponin complex and functional effects determined by measuring calcium 
binding and dissociation from the troponin C (TnC) subunit in reconstituted thin 
filaments. We found that mTnY134E decreases calcium sensitivity and accelerates 
calcium dissociation. These identified contractile effects of the Tyr-134 phosphorylation 
suggest that the phosphorylation of the TnI Tyr-134 residue may be significant to 
modulate contractile function and present a novel pathway to modulate heart function in 
the mouse heart that is not present in the human heart. 
 
Methods 
See chapter two.  
 
Results 
 TnI tyrosine phosphorylation is a novel mechanism to alter heart function. We 
have demonstrated the functional effects of human TnI pseudo-phosphorylation of Tyr-
26. It is important to compare the effects of TnI Tyr-26 across species to allow the 
interpretation of results found in rodent models to human cardiac function. To test the 
species effects of TnI on thin filament regulation, we generated, expressed and purified 
mouse, rat and human cardiac troponin subunits (Figs 1, 5 and 6). We investigated the 
effect of species troponin isoforms on calcium sensitivity by measuring calcium binding 
to TnC in the thin filament. Comparing human wild-type TnI (hTnWT) to the mouse 
wild-type TnI (mTnWT) we observed that the mouse cardiac TnI exhibits a similar 
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calcium-binding sensitivity to that of the human cardiac TnI (pCa50; hTnWT= 5.802 +/- 
0.037, mTnWT= 5.870 +/- 0.0478, n=19; p<0.05; Fig 7). Interestingly, when we 
measured the steady-state calcium binding of thin filaments containing wild-type rat 
cardiac TnI (rTnWT) we observed the rTnWT exhibited a calcium sensitivity that was 
significantly decreased compared to both human and mouse (Fig 7). This decreased Ca2+-
sensitive binding to TnC in the reconstituted thin filament containing rTnWT suggest that 
amino acid differences in the Tn complex between species are important in calcium 
sensitivity. These WT values provide critical insight to understanding the basic difference 
between species calcium sensitivity that are important in future studies by providing a 
basis to compare the functional effects of inter-species pseudo-phosphorylations on 
calcium sensitivity. 
In addition, we characterized the rate of Ca2+ dissociation from TnC of each 
species in the reconstituted thin filament in order to compare cardiac muscle relaxation 
kinetics. Stopped-flow fluorimetry was used to monitor the change in fluorescence of 
IAANS-labeled TnC in Ca2+ saturated thin filaments following rapid mixing with EGTA 
in order to access the rate of Ca2+ dissociation from TnC in the thin filament. Results 
demonstrate that thin filaments containing mTnWT exhibited the quickest Ca2+ 
dissociation from TnC followed by filaments containing hTnWT, while the slowest were 
thin filaments containing rTnWT (rate of calcium dissociation; mTnWT = 175.75 +/- 
8.79 /s, hTnWT = 108.77 +/-1.19 /s, rTnWT = 103.03 +/-4.08 /s; p>0.05; Fig 8, 9). These 
values are an important factor in the determination of how filaments containing 
phosphorylated tyrosine sites of TnI from different species affect cardiac muscle 
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relaxation. This data tells us that mouse cardiac relaxation happens much quicker than 
both human and rat cardiac relaxation.  
Similar to that in the human cardiac TnI, mouse cardiac TnI has a tyrosine-27 
residue capable of phosphorylation. Mouse cardiac TnI residue 27 is identical to human 
cardiac TnI residue 26 because mouse cardiac TnI contains an extra amino acid at reside 
25. We hypothesized the phosphorylation of this site will behave similarly to the 
phosphorylation of human TnI Tyr residues 26. To test the regulatory effects of TnI Tyr-
phosphorylation, we generated, expressed and purified mouse cardiac TnI containing 
phosphomimetic substitutions (Tyr to Glu or Tyr to Asp) (Fig 1). Purified proteins were 
used to form the troponin complex and functional effects determined by measuring 
calcium binding to TnC in reconstituted thin filaments. The effect of mouse cardiac Tn 
containing pseudo-phosphorylated TnI on Ca2+ regulation was determined by measuring 
the change in IAANS fluorescence upon steady-state Ca2+ binding to TnC in the 
reconstituted thin filament. The thin filaments containing mouse pseudo-phosphorylated 
TnI Tyr-27 to Glu (mTnY27E) exhibited a pCa50 of 5.69+/- 0.0380, n=7. Compared to the 
pCa50 exhibited by mTnWT, which was 5.870+/-.04783, hus, the mTnY27E pseudo-
phosphorylation decreases calcium binding to TnC in the reconstituted thin filament (Fig 
10). This decrease in calcium sensitivity observed in the mouse cardiac TnI upon tyrosine 
27 phosphorylation is parallel to the decrease in calcium sensitivity observed between 
hTnWT and hTnY26E. The change in pCa50 from hTnWT to hTnY26E is 0.326 (Fig 2). 
The change in pCa50 from mTnWT to mTnY27E is 0.18 (Fig 10). Thus, the functional 
effect of Tyr-26/27 phosphorylation is observed to similar degrees across species. 
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 The mouse TnI contains an additional Tyr residue that is not present in the 
human TnI that kinase prediction suggests may be an even better site for phosphorylation. 
This site, Tyr-134 in mouse cardiac Tn is a Phe-133 in human cardiac Tn. We 
hypothesized that the loss of this tyrosine residue in human TnI may be evolutionarily 
significant. To test this we generated, expressed and purified mouse cardiac Tn 
containing pseudo-phosphorylated TnI Tyr-134 to Glu (mTnY134E) for steady-state Ca2+ 
binding experimentation.  
The effect of thin filaments containing mTnY134E exhibited a pCa50 of 5.652 +/- 
0.0288, n=14 (Fig 10). This decrease in calcium sensitivity is nearly identical to the pCa50 
exhibited by mTnY27E, suggesting the phosphorylation of these sites decrease calcium 
sensitivity of the thin filament to a similar degree (Figs 11 and 12). Additionally, the 
effect of tyrosine phosphorylation observed in both mouse cardiac and human cardiac TnI 
appears to be proportional across species. Thus, our lab proposes that the phosphorylation 
of mouse cardiac Tn Tyr-27 and Tyr-134 is beneficial to heart function upon increased 
heart rate.  
We also looked at the dissociation of Ca2+ from TnC of each pseudo-
phosphorylation in isolated troponin and in the reconstituted thin filament in order to 
compare cardiac muscle relaxation kinetics [12,17]. The average change in IAANS 
fluorescence of stopped-flow Ca2+ dissociation from troponin containing mouse TnI 
(mTnWT, mTnY26E, mTnY134E) pseudo-phosphorylation shows no significant 
influence on calcium-dissociation from isolated troponin alone (rate of calcium 
dissociation: mTnWT = 36.75 +/- 0.85 /s, mTnY26E = 38.29 +/-0.68 /s, mTnY134E = 
34.41 +/-0.84 /s; p>0.05; Fig 13).  Additionally, reconstituted thin filaments containing 
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the varied pseudo-phosphorylated mouse cardiac TnI also did not differ in calcium 
dissociation form TnC. (rate of calcium dissociation: mTnWT = 175.75 +/- 8.79 /s, 
mTnY134E = 191.32 +/-14.93 /s; p>0.05; Figs 9 and 11). This set of data demonstrates 
there is a difference in calcium dissociation rates amongst species. However, unlike the 
effects of human TnI that was significantly faster in the presence of tyrosine pseudo-
phosphorylation, the rate of calcium dissociation from thin filaments containing mouse 
TnI Y134E pseudo-phosphorylation was not different from that of the non-
phosphorylated mouse TnI. These findings suggest that the pseudo-phosphorylation of 
TnI Tyr-134 has no effect on the relaxation of the mouse heart.  
 
Discussion  
In this study we demonstrate the following findings: 1) That mTnY27E exhibits a 
decrease in calcium sensitivity compared to mTnWT that is proportional in size to the 
decrease in calcium sensitivity seen in hTnY26E compared to hTnWT. 2) Thin filaments 
containing mTnY134E exhibit decreased calcium sensitivity compared to filaments 
containing mTnWT. 3) Thin filaments containing mTnY134E do not alter calcium 
dissociation.  
The first goal of this study aimed to assess the functional properties elicited by the 
phosphorylation of cardiac TnI in different species to provide a basis for comparison of 
pseudo-phosphorylation effects across species. Findings showed that the pseudo-
phosphorylation of mTnY26E has proportional functional effects as the pseudo-
phosphorylation of hTnY26E, decreasing calcium sensitivity binding similarly. These 
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results suggest that we can use the mouse as a model in future studies to compare 
functional effects of human tyrosine phosphorylation in TnI.   
The second major finding demonstrated that the pseudo-phosphorylation of 
mTnY134E exhibited decreased calcium sensitivity similarly to the pseudo-
phosphorylation of mTnY27E while not altering the rate of calcium dissociate. The 
findings give the first demonstration of mTnTyr-134 function and therefore may have an 
importance to alter cardiac function. Based upon these findings we suggest the effect of  
Tyr-134 phosphorylation to decrease calcium sensitivity will increase the force of cardiac 
contraction. Furthermore, since Tyr-134 phosphorylation does not affect calcium 
dissociation this increase in force production would occur without impairment of cardiac 
relaxation. Overall we proposed a decrease of TnI Tyr-134 phosphorylation would be 
beneficial in heart failure to increase contraction without impairment of relaxation.  
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Chapter 5- Discussion 
 
This study aimed to confirm the functional properties elicited by the 
phosphorylation of cardiac TnI Tyr residues [12,13], and further assess the functional 
properties elicited by the additional phosphorylation of TnI at Tyr-29 and Tyr-134. 
Findings of the study validate previous studies conducted by our lab. In addition, major 
findings demonstrate: 1) Mouse and human cardiac TnI have similar functional properties 
in the reconstituted thin filament. 2) Human TnI Tyr-26 and Tyr-29 pseudo-
phosphorylation decreases Ca2+-sensitive thin filament activation and accelerates thin 
filament deactivation. 3) Mouse TnI Tyr-27 and Tyr-134 pseudo-phosphorylation 
decreases Ca2+-sensitive thin filament activation. 4) Mouse TnI Tyr-27 pseudo-
phosphorylation decreases Ca2+-sensitive thin filament activation to a similar degree as 
that observed in human TnI. 5) Mouse TnI Tyr-134 pseudo-phosphorylation does not 
alter thin filament calcium dissociation.  
Regulatory effects of TnI Tyr-26 exemplify the first known myofilament protein 
tyrosine phosphorylation to directly modulate cardiac function, playing a significant role 
in contractile regulation of the heart. Previously demonstrated by our lab, the Tyr-26 
pseudo-phosphorylation mutation is sufficient to recapitulate Tyr-26 phosphate effects on 
Ca2+ sensitivity [12]. Therefore, for these experiments, pseudo-phosphorylation mutations 
were used. Additionally, our lab has also demonstrated that a non-phosphorylatable 
amino acid modification of the Tyr-26 residue to phenylalanine did not alter sensitivity 
and therefore, the effects of desensitization come from the negative charge at the residue 
[12]. This is important because knowing there is no effect on desensitization of the thin 
filament in the presence of a neutral charge at the residue; we can assume our findings 
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employing pseudo-phosphorylated TnI mimics the structure/function of TnI containing 
phosphate at this residue.  
Troponin I Tyr-26 phosphorylation has been demonstrated to be decreased in the 
failing human heart [12] and its functional effects are associated in with contractile 
modulation during heart failure [12]. The decrease in TnI Tyr-26 phosphorylation in heart 
failure may therefore contribute to the increased sensitivity of Ca2+ during heart failure 
and increased cardiac contraction. In addition, the presence of basally phosphorylated TnI 
Tyr-26 suggests it plays a role in maintaining normal heart function [12]. Our findings 
that TnI Tyr-29 phosphorylation also decreases calcium sensitivity and accelerates 
calcium dissociation suggest this phosphorylation may also play a role in the 
physiological modulation of normal heart function [13]. Furthermore, a decrease of TnI 
Tyr-29 phosphorylation during heart failure may therefore also be beneficial to improve 
cardiac contraction in heart failure.  
We first found that thin filaments containing the mouse cardiac TnI exhibit a 
similar calcium-binding sensitivity to that of filaments containing the human cardiac TnI. 
Additionally, steady state calcium binding of thin filaments containing wild-type rat 
cardiac TnI exhibited a calcium sensitivity that was significantly decreased compared to 
both human and mouse (Fig 7,14). This decreased calcium sensitive binding to TnC in the 
reconstituted thin filament containing wild-type rat cardiac TnI suggest that amino acid 
difference in the troponin (Tn) complex between species are important in calcium 
sensitivity. These WT values will be important in future studies for they provide critical 
insight to understanding the basic difference between species calcium sensitivity and 
suggest that each species must be independently validated. Overall, these WT values 
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provide a basis to begin to compare the functional effects of inter-species pseudo-
phosphorylations on calcium sensitivity.  
To test our hypothesis that the phosphorylation of additional TnI Tyrosine 
residues enhances thin filament deactivation to a similar degree as the TnI Tyr-26 residue 
we measured calcium dissociation from TnC in the thin filament. Our results 
demonstrated that while all mouse and human tyrosine residues tested decreased calcium 
sensitivity, only the human TnI tyrosine pseudo-phosphorylation of residues 26 and 29 
accelerates Ca2+ dissociation from TnC while the mouse TnI tyrosine phosphorylation of 
residue 134 did not. We propose that because human and mouse TnI tyrosine 
phosphorylation decreases Ca2+ sensitivity in reconstituted thin filaments to similar 
degrees, the mouse can be used as a model for tyrosine TnI phosphorylation calcium-
sensitivity functional effects in the human heart. We also propose that because the mouse 
TnI tyrosine phosphorylation of residue 134 does not alter calcium dissociation and 
human TnI tyrosine phosphorylation or residues 26 or 29 do, there is a differential effect 
of the specific tyrosine residue phosphorylated on the rate of calcium dissociation from 
TnC. These findings suggest that the similar sensitivity change between human and 
mouse tyrosine phosphorylation, but difference in dissociation effects, support species 
specific changes in the thin filament mechanisms that control calcium dissociation and 
potentially cardiac muscle relaxation.   
Our last study focusing on Tyr-134 in mouse cardiac TnI found that the 
phosphorylation of residue 134 has a decreased calcium-binding sensitivity and an 
unaltered calcium dissociation from TnC. Unlike the mouse, the corresponding residue in 
human TnI is a non-phosphorylatable phenylalanine. We predicted this reside in TnI was 
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altered due to specific functional effects required for human cardiac contraction and 
relaxation compared to the faster heart rate of the mouse. We believe this site was either 
evolutionarily gained in the mouse for this ability or evolutionarily lost in the human for 
it was not needed. The evolution loss or gain of this phosphorylatable tyrosine residue in 
human cardiac TnI may therefore be important to human heart contraction and the re-
introduction of the phosphorylatable tyrosine may serve as a target to modulate cardiac 
contractile properties.  
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Chapter 6-Future Directions and Conclusion 
 
Future Direction  
Additional studies are needed to extend the results obtained from these 
experiments. Calcium-binding experiments are needed to analyze the additional 
phosphorylatable tyrosine residue on the human TnI, Tyr-112, to determine if the 
phosphorylation at this site has similar functional effects observed to the results seen 
from this study for the phosphorylation of the Tyr-26 and Tyr-29 sites. Calcium-binding 
experiments are also needed to analyze the effect of the phosphorylation of human TnI 
Phe-133 by mutation to tyrosine and it phosphorylation and comparison of its functional 
effects to those of the mouse TnI Tyr-134 residue when phosphorylated. Such 
experiments would support the need to investigate targeted phosphorylation of additional 
human TnI tyrosine residues to modulate cardiac contraction in the future.  
Furthermore, future studies should consider calcium sensitivity of the thin 
filament containing a combination of phosphorylated tyrosine sites as they would likely 
occur in the heart. Incorporating multiple pseudo-phosphorylations has the potential to 
nullify or amplify the effects of a single tyrosine residue phosphorylation so it would be 
important to assess the crosstalk of multiple phosphorylated sites present in human and 
mouse TnI.  
Lastly, the experiments conducted in this report were all conducted in vitro to 
determine if there was a functional effect. Prospective studies should be conducted in 
vivo experimentation to determine effect of TnI phosphorylation on cardiac myocyte 
contraction rates on basal and diseased hearts.  
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Conclusion 
In the data reported here, we demonstrate human TnI tyrosine phosphorylation 
functions similarly to the phosphorylation of mouse TnI tyrosine residues, resulting in 
decrease Ca2+ sensitivity and accelerated dissociation in the reconstituted thin filament. In 
addition, we demonstrate the unique Tyr-134 residue in mouse TnI exhibits decreased 
calcium sensitivity of the thin filament without altering calcium dissociation.. These 
effects of thin filament phosphorylation of TnI tyrosine residues to alter myofilament 
regulation and their potential effect on cardiac contractile function present a potentially 
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      Figure legends 
 
Fig 1. SDS-PAGE gel demonstrating purity of expressed proteins. HcTnT; 
purified human cardiac TnT, HcTnI WT; purified human cardiac WT TnI, HcTnI 
Y26D; purified human cardiac TnI Y26D, HcTnI Y26E; purified human cardiac TnI 
Y26E, HcTnI Y29E; purified human cardiac TnI Y29E, and HcTnC; purified human 
cardiac TnC. 
 
Fig. 2 Steady-state thin filament calcium binding of human TnI. Change in 
IAANS fluorescence resulting from Ca2+ binding to TnC in thin filaments containing 
non-phosphorylated human wild-type TnI (HcTnI WT, grey circle), pseudo-
phosphorylated human Tyr-26 to Asp TnI (HcTnI Y26D, red circle), pseudo-
phosphorylated human Tyr-26 to Glu TnI (HcTnI Y26E, black circle) and pseudo-
phosphorylated human Tyr-29 to Glu TnI (HcTnI Y29E, pink). 
 
Fig 3. Average change in IAANS fluorescence of isolated human troponin by 
stopped-flow calcium dissociation. Human TnI (Wt, Y26D, Y26E, Y29E). Pseudo-
phosphorylation shows no significant influence on calcium-dissociation from 
troponin.  
 
Fig 4. Average change in IAANS fluorescence in human thin filaments by 
stopped-flow calcium dissociation. Human troponin in reconstituted thin filament 
(WT, Y26D, Y26E, Y29E). Pseudo-phosphorylation shows significant influence on 
calcium-dissociation from Troponin.  
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Fig. 5 SDS- PAGE gel demonstrating purity of expressed proteins. RcTnI; 
purified rat cardiac TnI, RcTnT; purified rat cardiac TnT and RcTnC; purified rat 
cardiac TnC. 
 
Fig 6. SDS-PAGE gel demonstrating purity of expressed proteins. McTnT; 
purified mouse cardiac TnT, McTnI WT; purified mouse cardiac WT TnI, McTnI 
Y26E; purified mouse cardiac TnI Y26E, McTnI Y134E; purified mouse cardiac TnI 
Y134E, McTnC; and purified mouse cardiac TnC. 
 
Fig 7. Steady-state thin filament calcium binding of human, mouse and rat TnI.  
Change in IAANS fluorescence resulting from Ca2+ binding to TnC in thin filaments 
containing non-phosphorylated human wild-type TnI (HcTnI WT, grey circle), non-
phosphorylated mouse wild-type TnI (McTnI WT, red circle) and non-phosphorylated 
rat wild-type TnI (RcTnI, black circle). 
 
Fig. 8 Representative change in IAANS fluorescence of human thin filaments by 
stopped flow calcium dissociation. Thin filaments containing Human Wt, Human 
Y29E and Human Y26E. Traces are staggered for clarity. 
 
Fig. 9 Representative change in IAANS fluorescence of mouse thin filaments by 
stopped flow calcium dissociation. Thin filaments containing Mouse Wt and Mouse 
Y134E. Traces are staggered for clarity. 
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Fig. 10 Steady-state thin filament calcium binding of mouse WT and pseudo-
phosphorylated TnI. Change in IAANS fluorescence resulting from Ca2+ binding to 
TnC in thin filaments containing non-phosphorylated mouse wild-type TnI (McTnI 
WT,red circle), pseudo-phosphorylated mouse Tyr-26 to Glu TnI (McTnI Y26E, grey 
circle) and pseudo-phosphorylated mouse Tyr-134 to Glu TnI (McTnI Y134E, black 
circle). 
 
Fig 11. Average change in IAANS fluorescence in mouse thin filament by 
stopped-flow calcium dissociation. Mouse troponin in reconstituted thin filament 
(WT, Y134E). Pseudo-phosphorylation shows significant influence on calcium-
dissociation from Troponin.  
 
Fig 12. Calcium required to reach 50% maximal activation (pCa50) in steady-
state calcium-binding titrations. McTnWt (n=19), McTnY26E (n=14) and 
McTnY134E (n=7). 
 
Fig 13. Average change in IAANS fluorescence of mouse isolated troponin by 
stopped-flow calcium dissociation. Mouse TnI (Wt, Y26E, Y134E). Pseudo-
phosphorylation shows no significant influence on calcium-dissociation from 
troponin.  
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Fig 14. Calcium required to reach 50% maximal activation (pCa50) in steady-
state calcium-binding titrations. HcTnWT (n=14), HcTnY26D (n=3), HcTnY26E 
(n=6) and HcTnY29E (n=3).  
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Figure 7.  
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Figure 12.  
 
  
	   54	  





	   55	  
Figure 14.  
 
 
 
